GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Core Insights - GRI Bio, Inc. emphasizes the significance of interim data from its ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) [1][4] - The company is focused on developing Natural Killer T (NKT) cell modulators to treat inflammatory, fibrotic, and autoimmune diseases [4][6] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company aiming to transform the treatment of inflammatory, fibrotic, and autoimmune diseases [6] - The company's lead program, GRI-0621, is an oral therapeutic designed to inhibit iNKT cell activity for treating IPF, a disease with significant unmet medical needs [6] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [6]